Posted by Michael Wonder on 09 Feb 2023
Eylea (aflibercept) injection approved as the first pharmacological treatment for preterm infants with retinopathy of prematurity by the FDA
8 February 2023 - Eylea now approved to treat five retinal conditions caused by ocular angiogenesis.
Regeneron Pharmaceuticals today announced that the US FDA has approved Eylea (aflibercept) Injection to treat preterm infants with retinopathy of prematurity.
